---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-001316"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:20:04.647034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025

## Summary
- Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.
- Cash $59.1M as of Sep 30, 2024; expected to fund operations into Q3 2025.
- Phase 3 ENSURE futility analysis positive: IDMC recommends continuation without sample size increase.
- Top-line data from Phase 2 CALLIPER (PMS) expected April 2025; ENSURE-1 completion Q2 2026.
- New leadership: Jason Tardio appointed COO/President; Werner Gladdines promoted to CDO.

## SEC filing metadata
- accession: 0001193805-24-001316
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380524001316/0001193805-24-001316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380524001316/e663991_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-001316
- JSON: https://secwatch.observer/filing/0001193805-24-001316.json
- Plain text: https://secwatch.observer/filing/0001193805-24-001316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.